PETS FINANCIAL STATEMENTS

PetMed Express Inc — balance sheet, income statement and cash flow trends

PETSPetMed Express Inc

🇺🇸 USA · NASDAQ · Healthcare · Pharmaceutical Retailers

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue179 M $-27.5%

Gross Profit43.1 M $-33.4%

Operating Income-31.4 M $-5,760.4%

EBITDA-17.2 M $-319.1%

Net Income-57.3 M $-16,146.5%

Peer Comparison· Pharmaceutical Retailers

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PETS	-22.7%	24.1%	-9.6%	-32.0%
RTALB	24.0%	35.1%	9.0%	136.3%
ANGEN	11.7%	58.8%	9.8%	-45.0%
HIK	7.4%	41.4%	20.0%	12.0%
TRILC	32.0%	33.8%	28.5%	-2.2%
LKMNH	19.8%	18.8%	26.4%	3.2%
Industry median	-22.7%	24.1%	-9.6%	-32.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PETS	-22.7%	24.1%	-9.6%	-32.0%
TELA	13.5%	67.3%	-40.2%	-49.3%
OTLK	-2.1%	-360.9%	-18,634.1%	-18,297.5%
PDSB	-100.0%	—	—	—
SCLX	-33.2%	59.7%	-984.4%	-1,239.4%
ARAY	-7.9%	26.8%	-1.5%	-10.8%
Industry median	-22.7%	24.1%	-9.6%	-32.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity28.9 M $36%
Current Liabilities52 M $64%
Long-term Liabilities217 K $0%

Key Figures

YoY change

Total Assets81.2 M $-43.9%

Total Liabilities52.3 M $+7.5%

Total Equity28.9 M $-69.9%

Cash & ST Investments21.4 M $-57.3%

Total Debt535 K $-51.6%

Net Debt-20.9 M $—

Peer Comparison· Pharmaceutical Retailers

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PETS	0.84	1.8%	1.21	35.6%
RTALB	1.21	1.2%	0.90	84.9%
ANGEN	2.31	28.1%	4.71	67.2%
HIK	1.82	61.8%	1.87	45.7%
TRILC	0.99	207.6%	2.71	23.5%
LKMNH	0.83	99.0%	1.96	41.6%
Industry median	0.84	1.8%	1.21	35.6%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PETS	0.84	1.8%	1.21	35.6%
TELA	3.61	-1,084.3%	-0.52	-7.4%
OTLK	0.54	-93.8%	-0.31	-132.4%
PDSB	2.26	407.5%	0.21	15.8%
SCLX	0.08	-42.7%	-0.31	-84.9%
ARAY	1.42	437.3%	-22.14	9.3%
Industry median	0.84	1.8%	1.21	35.6%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-28.4 M $-687.6%

Capital Expenditures4.7 M $+17.1%

Free Cash Flow-33 M $-3,956.2%

Dividends Paid-19 K $-109.8%

Peer Comparison· Pharmaceutical Retailers

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PETS	-15.9%	-18.4%	2.6%	49.6%
RTALB	58.5%	88.6%	10.8%	42.9%
ANGEN	40.2%	-21.2%	61.5%	-89.3%
HIK	11.6%	5.8%	5.8%	96.8%
TRILC	10.9%	-0.3%	11.2%	-505.5%
LKMNH	8.4%	-9.7%	18.2%	264.8%
Industry median	-15.9%	-18.4%	2.6%	49.6%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PETS	-15.9%	-18.4%	2.6%	49.6%
TELA	-36.7%	-37.4%	0.7%	74.5%
OTLK	-14,121.8%	-14,121.8%	0.0%	77.2%
PDSB	—	—	—	13,162.3%
SCLX	-9.7%	-18.1%	10.1%	0.8%
ARAY	-4.5%	-6.8%	2.3%	41.4%
Industry median	-15.9%	-18.4%	2.6%	49.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PETS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.